241 related articles for article (PubMed ID: 32409773)
1. The therapeutic potential of BRD4 in cardiovascular disease.
Lin S; Du L
Hypertens Res; 2020 Oct; 43(10):1006-1014. PubMed ID: 32409773
[TBL] [Abstract][Full Text] [Related]
2. Multicenter Preclinical Validation of BET Inhibition for the Treatment of Pulmonary Arterial Hypertension.
Van der Feen DE; Kurakula K; Tremblay E; Boucherat O; Bossers GPL; Szulcek R; Bourgeois A; Lampron MC; Habbout K; Martineau S; Paulin R; Kulikowski E; Jahagirdar R; Schalij I; Bogaard HJ; Bartelds B; Provencher S; Berger RMF; Bonnet S; Goumans MJ
Am J Respir Crit Care Med; 2019 Oct; 200(7):910-920. PubMed ID: 31042405
[No Abstract] [Full Text] [Related]
3. A patent review of BRD4 inhibitors (2013-2019).
Lu T; Lu W; Luo C
Expert Opin Ther Pat; 2020 Jan; 30(1):57-81. PubMed ID: 31815566
[No Abstract] [Full Text] [Related]
4. Novel strategies targeting bromodomain-containing protein 4 (BRD4) for cancer drug discovery.
Liang D; Yu Y; Ma Z
Eur J Med Chem; 2020 Aug; 200():112426. PubMed ID: 32502863
[TBL] [Abstract][Full Text] [Related]
5. Privileged Scaffolds Targeting Bromodomain-containing Protein 4.
Wang R; Wang YA; Xu YG; Shi L
Curr Top Med Chem; 2022; 22(7):600-627. PubMed ID: 35139799
[TBL] [Abstract][Full Text] [Related]
6. Bromodomain-Containing Protein 4: A Druggable Target.
Shi Y; Liu J; Zhao Y; Cao J; Li Y; Guo F
Curr Drug Targets; 2019; 20(15):1517-1536. PubMed ID: 31215391
[TBL] [Abstract][Full Text] [Related]
7. BRD4 bimodal binding at promoters and drug-induced displacement at Pol II pause sites associates with I-BET sensitivity.
Khoueiry P; Ward Gahlawat A; Petretich M; Michon AM; Simola D; Lam E; Furlong EE; Benes V; Dawson MA; Prinjha RK; Drewes G; Grandi P
Epigenetics Chromatin; 2019 Jul; 12(1):39. PubMed ID: 31266503
[TBL] [Abstract][Full Text] [Related]
8. Apabetalone (RVX-208) reduces vascular inflammation in vitro and in CVD patients by a BET-dependent epigenetic mechanism.
Tsujikawa LM; Fu L; Das S; Halliday C; Rakai BD; Stotz SC; Sarsons CD; Gilham D; Daze E; Wasiak S; Studer D; Rinker KD; Sweeney M; Johansson JO; Wong NCW; Kulikowski E
Clin Epigenetics; 2019 Jul; 11(1):102. PubMed ID: 31300040
[TBL] [Abstract][Full Text] [Related]
9. Dual-target inhibitors of bromodomain-containing protein 4 (BRD4) in cancer therapy: Current situation and future directions.
Jin W; Tan H; Wu J; He G; Liu B
Drug Discov Today; 2022 Jan; 27(1):246-256. PubMed ID: 34438075
[TBL] [Abstract][Full Text] [Related]
10. Stromal induction of BRD4 phosphorylation Results in Chromatin Remodeling and BET inhibitor Resistance in Colorectal Cancer.
Wang W; Tang YA; Xiao Q; Lee WC; Cheng B; Niu Z; Oguz G; Feng M; Lee PL; Li B; Yang ZH; Chen YF; Lan P; Wu XJ; Yu Q
Nat Commun; 2021 Jul; 12(1):4441. PubMed ID: 34290255
[TBL] [Abstract][Full Text] [Related]
11. Atomistic insights into the selective therapeutic activity of 6-(2,4-difluorophenoxy)-5-((ethylmethyl)pyridine-3-yl)-8-methylpyrrolo[1,2-a]pyrazin-1(2H)-one towards bromodomain-containing proteins.
Akawa OB; Soremekun OS; Olotu FA; Soliman MES
Comput Biol Chem; 2021 Dec; 95():107592. PubMed ID: 34710811
[TBL] [Abstract][Full Text] [Related]
12. Emerging roles of and therapeutic strategies targeting BRD4 in cancer.
White ME; Fenger JM; Carson WE
Cell Immunol; 2019 Mar; 337():48-53. PubMed ID: 30832981
[TBL] [Abstract][Full Text] [Related]
13. Bromodomain-containing protein 4 and its role in cardiovascular diseases.
Li L; Xie W; Gui Y; Zheng XL
J Cell Physiol; 2021 Jul; 236(7):4829-4840. PubMed ID: 33345363
[TBL] [Abstract][Full Text] [Related]
14. Targeting Hippo coactivator YAP1 through BET bromodomain inhibition in esophageal adenocarcinoma.
Song S; Li Y; Xu Y; Ma L; Pool Pizzi M; Jin J; Scott AW; Huo L; Wang Y; Lee JH; Bhutani MS; Weston B; Shanbhag ND; Johnson RL; Ajani JA
Mol Oncol; 2020 Jun; 14(6):1410-1426. PubMed ID: 32175692
[TBL] [Abstract][Full Text] [Related]
15. Selective inhibition of the BD2 bromodomain of BET proteins in prostate cancer.
Faivre EJ; McDaniel KF; Albert DH; Mantena SR; Plotnik JP; Wilcox D; Zhang L; Bui MH; Sheppard GS; Wang L; Sehgal V; Lin X; Huang X; Lu X; Uziel T; Hessler P; Lam LT; Bellin RJ; Mehta G; Fidanze S; Pratt JK; Liu D; Hasvold LA; Sun C; Panchal SC; Nicolette JJ; Fossey SL; Park CH; Longenecker K; Bigelow L; Torrent M; Rosenberg SH; Kati WM; Shen Y
Nature; 2020 Feb; 578(7794):306-310. PubMed ID: 31969702
[TBL] [Abstract][Full Text] [Related]
16. 3-Hydroxyisoindolin-1-one derivates: Synthesis by palladium-catalyzed CH activation as BRD4 inhibitors against human acute myeloid leukemia (AML) cells.
Chen P; Yang Y; Yang L; Tian J; Zhang F; Zhou J; Zhang H
Bioorg Chem; 2019 May; 86():119-125. PubMed ID: 30690335
[TBL] [Abstract][Full Text] [Related]
17. A Structure-based Design Approach for Generating High Affinity BRD4 D1-Selective Chemical Probes.
Cui H; Divakaran A; Hoell ZJ; Ellingson MO; Scholtz CR; Zahid H; Johnson JA; Griffith EC; Gee CT; Lee AL; Khanal S; Shi K; Aihara H; Shah VH; Lee RE; Harki DA; Pomerantz WCK
J Med Chem; 2022 Feb; 65(3):2342-2360. PubMed ID: 35007061
[TBL] [Abstract][Full Text] [Related]
18. Epigenetic Reader Bromodomain-Containing Protein 4 in Aging-Related Vascular Pathologies and Diseases: Molecular Basis, Functional Relevance, and Clinical Potential.
Zheng X; Diktonaite K; Qiu H
Biomolecules; 2023 Jul; 13(7):. PubMed ID: 37509171
[TBL] [Abstract][Full Text] [Related]
19. Molecular Dynamic Simulations of Bromodomain and Extra-Terminal Protein 4 Bonded to Potent Inhibitors.
Chen S; He Y; Geng Y; Wang Z; Han L; Han W
Molecules; 2021 Dec; 27(1):. PubMed ID: 35011350
[TBL] [Abstract][Full Text] [Related]
20. Dissecting the Role of BET Bromodomain Proteins BRD2 and BRD4 in Human NK Cell Function.
Cribbs AP; Filippakopoulos P; Philpott M; Wells G; Penn H; Oerum H; Valge-Archer V; Feldmann M; Oppermann U
Front Immunol; 2021; 12():626255. PubMed ID: 33717143
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
